Hepatitis D virus in Bulgaria: virology, epidemiology and pathogenesis in chronic HBV carriers with liver dysfunction by Tsaneva-Damyanova, Denitsa et al.
12 
Scripta Scientifica Medica, 2020;52(3):12-18
Medical University of Varna
ORIGINAL ARTICLES
HEPATITIS D VIRUS IN BULGARIA:  
VIROLOGY, EPIDEMIOLOGY AND PATHOGENESIS  
IN CHRONIC HBV CARRIERS WITH LIVER DYSFUNCTION
Denitsa Tsaneva-Damyanova1, Zhivka Stoykova1,2, Irina Ivanova3,  
Tsvetelina Kostadinova4, Liliya Ivanova1
1Department of Microbiology and Virology, Faculty of Medicine,  
Medical University of Varna 
2Laboratory of Clinical Virology, St. Marina University Hospital 
3Second Department of Internal Diseases, Faculty of Medicine,  
Medical University of Varna 
4TRS Medical Laboratory Assistant, Medical College, Medical University of Varna
ABSTRACT
INRODUCTION: Hepatitis D (HDV) is the most interesting and unique among animal viruses. It causes 
viral hepatitis D only in individuals already infected with HBV (hepatitis B). This dual  infection leads to 
the most aggressive hepatic dysfunction of all human viral hepatitis.
AIM: This study was made to outline the hepatitis D virus among patients with chronic liver disorders in 
northeastern Bulgaria, in the sight of virus epidemiology, pathogenicity and viral genotype.
MATERIALS AND METHODS: This is a retrospective study conducted between 2013-2019 at St. Marina 
University Hospital,Varna, Bulgaria. We have analyzed 418 serum samples from 391 patients with chronic 
liver disease using ELISA, PCR and HDV sequencing and genotyping.
RESULTS AND DISCUSSION: From 391 patients with chronic liver abnormalities, 16.6% (95% CI: 15.9% - 
23.8%, n=65) had an etiological association with HDV in ELISA. We found HDV RNA positive results in 63 
out of all 65 anti-HDV Ab (antibody) positive patients (96.9%). Twenty-four of them, or 38.1% (95% CI: 26.1% 
- 51.2%, n=24), were on antiviral HBV/HDV therapy. For five of them, or 20.8% (95% CI: 7.1% - 42.2%, n=5), 
HDV genotype I was found.
CONCLUSION: HDV infection has still many mysteries to discover - in terms of pathogenesis, clinical 
outcome in chronic HBV/HDV-infected individuals, as well as genotype variations and their role in avoiding 
immune elimination of the virus. All these unanswered questions pose a great challenge to the scientific 
thought and efforts of humankind to reduce and gradually eliminate viral hepatitis D.
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INTRODUCTION
Hepatitis D virus (HDV) infection is still a seri-
ous global problem affecting 15-20 million individu-
als worldwide (1). While hepatitis B (HBV) is a DNA 
virus coding for several proteins, HDV is a circular 
single strand negative-sense ribonucleic acid (RNA), 
group V, genus: Deltavirus, that codes for a single 
protein-HDV antigen (HDAg). The nucleocapsid is 
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op (1). Despite the various widely discussed mecha-
nisms, the pathogenesis of HDV-induced hepatic im-
pairment has not yet been fully defined. In Bulgaria 
HDV is not so fully investigated (only by a few small 
inquiries) and there is not enough data for viral epi-
demiology, pathogenesis and especially for circulat-
ing HDV genotypes, a fact that underlines the rele-
vance and importance of our project.
AIM 
This study was made to outline hepatitis D vi-
rus distribution among patients with chronic liver 
disorders in northeastern Bulgaria, in the sight of vi-
rus epidemiology, pathogenicity and HDV genotype.
MATERIALS AND METHODS
This is a retrospective study conducted between 
2013-2019 at St. Marina University Hospital, Varna, 
Bulgaria and in the hospital’s laboratories of Clini-
cal Virology and Clinical Immunology. We have an-
alyzed 1056 serum samples in order to determine the 
relative share of patients with chronic HBV and HDV 
infection in northeastern Bulgaria. In 418 serum 
samples from 391 patients with chronic liver disease 
we have detected HDV using ELISA (enzyme-linked 
immunosorbent assay), PCR (polymerase chain re-
action - real-time PCR and nested PCR) and HDV 
sequencing and genotyping of five patients (n=5). In 
our study the genotype assignment was based on the 
analysis of the sequences that corresponded to nu-
cleotides between 906 and 1256. Analysis of the se-
quences encoding the C-terminal half of the delta 
antigen of HDV genome of five individuals was made 
via direct sequencing of isolates. We have analyzed 
the sequences via BLAST analysis in NCBI (National 
Center for Biothechnology and Information).
Ethics Statement
The current study and the corresponding re-
sults reported has been conducted in an ethical and 
responsible manner, and is in full compliance with 
all relevant codes of experimentation and legislation, 
coordinated and approved by the Commission for 
Scientific Ethics at the Medical University of Varna 
(Protocol/Decision No. 61, from 30.03.17), in compli-
ance with the requirements of article 28 of the Health 
Law. All of the participants provided written in-
formed consent for the use of their blood and blood 
components (such as sera and plasma).
made up of two forms - HDAg-L and HDAg-S. They 
are the only proteins encoded by HDV. HDV RNA 
contains 6 ORFs (open reading frames), 3 of the ge-
nomic chain and 3 of the anti-sense chain (2). The 
virus causes viral hepatitis D only in individuals al-
ready infected with HBV. This dual infection leads to 
the most aggressive hepatic dysfunction of all types 
of human viral hepatitis, causing fibrosis, cirrhosis 
and hepatocellular carcinoma (HCC). Patients with 
HBV and HDV chronic infection have a twofold 
higher risk of developing cirrhosis, a threefold high-
er risk of developing HCC and a twofold increased 
mortality rate compared with HBV monoinfected 
individuals (3). HDV infection remains one of the 
main causes of death from viral hepatitis and an in-
dication of liver transplantation. The severity of liv-
er disease caused by HBV/HDV is thought to be as-
sociated with the HDV genotype and viral loads (4). 
There are eight different HDV genotypes worldwide. 
Up to now, the inverse correlation between HDV and 
HBV viremia has not been fully elucidated (5). There 
are multiple routes of transmission of HDV, predom-
inantly parenteral route. The same type of spreading 
mechanisms determines the possibility of simulta-
neous HBV/HDV infection (co-infection), as well as 
HBV/HDV superinfection in chronic HBV carriers. 
Susceptibility to hepatitis D virus is typical for all age 
groups, but the disease primarily affects children and 
adolescents (6). Endemic zones for HDV include the 
countries of the Mediterranean basin, Russia, Roma-
nia, Southern Italy, Central Africa, as well as Western 
Brazil (7). The pathological changes during hepatitis 
D are restricted to the liver and this is the only organ 
in which HDV virus replicates (8). Most researchers 
believe that HDV genomic replication does not have 
a cytopathic effect on hepatocytes. Thus, both types 
of specific immunity - humoral and cellular - can 
be involved in the pathogenesis of HDV infection 
(9). Induction of INF-γ, TNF-α, IL-2, IL-10 in hepa-
tocytes to suppress non-cytolytically HBV replica-
tion has been demonstrated in the liver of transgenic 
mice (10). HLA antigens (human leukocyte antigen) 
A1, DR3 and B18, from MHC I (major histocompat-
ibility complex-I), are associated with more severe 
HDV infection outcomes (11). By means of dysregu-
lation of the kappa B (NF-κB) nuclear factor, which 
is associated with inflammation and carcinogenesis 
processes, hepatocellular carcinoma can also devel-
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Statistical Analysis
Statistical analyses were performed using SPSS 
v.23. Quantitative variables were expressed as mean 
±SD or median (range) as appropriate and the qual-
itative variables were reported as a number, relative 
proportion (%) and confidence intervals (95% CI). 
Data were analyzed by t-test, Pearson’s χ2 test, Spear-
man’s rank correlation (r). Two-sided p-values <0.05 
were considered statisti cally significant. Figures and 
tables were made using Microsoft Office Pack 2010.
RESULTS
Our retrospective study in Varna and north-
eastern part of Bulgaria of 1056 serum samples with 
clinical and laboratory data on liver disease (21 - 
86 years), mean age 51.6 y. (SD±14.37), showed an 
ethological relationship with HBV (HBsAg carrier, 
HBV monoinfection) in 23.6% (116/492) of the test-
ed patients. 
Of all patients tested for HDV (n=391) with 
proven liver disease, 16.6% (95% CI: 15.9% - 23.8%, 
n=65) had an etiological association with HDV in 
ELISA. The distribution of the HDV tested individu-
als as per their age is presented on Table 1. The high-
er prevalence of hepatitis D in younger and middle-
aged patients 29-48 y. indicates that dual infection is 
predominantly acquired at a younger age and mainly 
in people with risky behaviour. A statistically signifi-
cant difference was found between the anti-HDV Ab 
seropositivity of individuals in the 29-38 age group 
and that in the other age groups (Pearson’s χ2=4.48, 
p=0.03 <0.5). 
From 65 registered anti-HDV positive patients, 
we found HDV RNA positive results in 63 of them in 
PCR - 96.9% (95% CI: 89.3% - 89.6%). A higher prev-
alence of hepatitis D was found in patients aged 29-
38 years. From them, males - 63.1% (95% CI: 50.2% 
- 74.7%, n=41), females - 36.9% (95% CI: 25.3% - 
49.8%, n=24), between 24 and 68 years of age, mean 
age 47.36 y. (SD±10.93). Pearson’s χ2 analysis found no 
statistically significant differences between gender 
and anti-HDV Ab positive results (X2=1.4, p=0.22, 
p>0.05). 
Twenty-four of these 63 PCR HDV RNA posi-
tive patients or 38.1% (95% CI: 26.1% - 51.2%, n = 24) 
from 28 to 68 years of age (mean age 44.45±SD 12.17) 
were on antiviral HBV/HDV therapy. The distribu-
tion of HBV/HDV positive patients (n=24) enrolled 
in antiviral therapy in this study based on laboratory, 
histologically and clinical ground is presented on Fig. 
1. Clinical and laboratory assessment was made ac-
cording to Child-Turcotte-Pugh (CTP score for cir-
rhosis mortality) criteria. According to the CTP clas-
sification, in stage A liver cirrhosis were 33.3% (95% 
CI: 15.6% - 55.3%, n=8), in stage B - 12.5% (95% CI: 
2.7% - 32.4%, n=3), and in stage C - 16.7% (95% CI: 
4.7% - 37.4%, n=4). In 37.5% (95% CI: 18.8% - 59.4%, 
n=9) of the patients, chronic hepatitis was reported 
progressing to cirrhosis. A total of 62.5% of the pa-
Age groups 
(years) HDV tested 
Anti-HDV Ab positive
HDV (positive) Relative share %, (95%CI)
18 – 28 y. 32 2 6.3% (0.8% – 20.8%)
29 – 38 y. 67 17 25.4% (15.5% – 37.5%)
39 – 48 y. 68 14 20.6% (11.7% – 32.1%)
49 – 58 y. 117 20 17.1% (10.8% – 25.2%)
59 – 68 y. 82 11 13.4% (6.9% – 22.7%)
above 68 y. 25 1 4.0% (0.1% – 20.4%)
Total 391 65 16.6% (13.1% – 20.7%)
Table 1. Distribution of the HDV tested individuals as per their age
Fig. 1. Stage and severity of chronic liver disease in 
patients with dual HBV/HDV infection
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tients (95% CI: 40.6% - 81.2%, n=15) were with al-
ready diagnosed liver cirrhosis.
These 24 patients were classified into A, B and 
C groups, based on the average values of bilirubin, al-
bumin and prothrombin time (international normal-
ized ratio (INR)). Ascites and encephalopathy were 
also marked according to their severity. Liver cirrho-
sis belongs to diseases for which patients’ survival is 
a matter of principle. There are prognostic models 
for estimating the probability of death in a certain 
time interval. They are based on an assessment of 
the functional “reserve” of the liver. Among a series 
of new prognostic systems, the Model for End Stage 
Liver Disease (MELD) system is offered as the most 
promising alternative to the CTP criteria in patients 
with cirrhosis or complicated liver disease. Summa-
ry data for our 24 patients, based on MELD score, are 
presented in Table 2. Patients with worsening prog-
nosis, according to the MELD system, either had de-
compensated liver disease (n=7, as per our data), or 









2 S.D.A 57 31.0 42.0 1.28 No No
3 G.A.S 35 34.0 38.0 1.34 No No
4 M.S.S 37 60.0 28.0 1.82 No No
5 K.A.A 52 15.0 44.0 1.0 No No
6 V.B.S 47 23.0 36.0 1.10 No No
7 J.F.B 50 24.0 34.0 1.15 No No
8 H.B.G 63 22.0 32.0 1.17 No No
9 T.S.R 33 8.0 46.0 1.03 No No
10 D.A.K 33 39.0 34.0 1.25 Yes No
11 G.E.D 60 8.0 44.0 1.04 No No
12 R.I.P 35 7.0 47.0 1.06 No No
13 K.M.H 36 7.0 47.0 1.06 No No
14 N.N.A 29 17.0 44.0 2.93 No No
15 A.S.S 68 12.0 41.0 1.32 No No
16 H.S.K 59 31.0 47.0 1.04 No No








19 O.A.M 38 8.0. 45.0 0.99 No No




21 H.V.M 45 71.0 20.0 1.76 Yes No
22 G.S.V 38 6.0. 37.0 1.27 No No




24 M.H.S 41 19.0 31.0 0.97 Yes No
Table 2. Clinical and laboratory data for the tested HBV/HDV positive patients (n=24), as per MELD prognostic system, 
for assessment of liver function and patient’s survival
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had already died (n=5). The results of the Child-Tur-
cotte-Pugh system, as well as MELD, are the two liv-
er systems that are mainly used to assess the severity 
of the disease in patients with liver cirrhosis.
All of the five dead patients - 20.8% (95% CI: 
7.1% - 42.2%, n=5), with chronic dual HBV/HDV vi-
ral infection (3 women and 2 men; mean age 45,8 
years; range 28-61 years) were genetically analyzed 
via direct sequencing of the HDV RNA amplicons. 
The genotype assignment was based on the anal-
ysis of the sequences that corresponded to nucleo-
tides between 906 and 1256. Analysis of the sequenc-
es encoding the C-terminal half of the delta antigen 
of HDV genome of five individuals was made via di-
rect sequencing of isolates. We have analyzed the se-
quences via BLAST analysis in NCBI. Comparison of 
the obtained in our survey HDV determined that all 
of the tested individuals were closely related to HDV 
genotype I, circulating in our neighboring countries 
(Greece, Turkey), as well as in Europe (Tablе 2). Nu-
cleotide similarity among the five isolated sequenc-
es ranged from 89% to 96% (mean 93%). The disease 
pattern associated with infection by HDV genotype 
I appears to be highly variable. These five patients 
were at different stageс of liver dysfunction – 40.0% 
(95% CI: 0.5% - 71.6%, n=2) with chronic hepatitis, 
stage A - 20.0% (95% CI: 0.5% - 71.6%, n=1), stage B 
- 20.0% (95% CI: 0.5% - 71.6%, n=1), and stage C – 
20.0% (95% CI: 0.5% - 71.6%, n=1) of liver cirrhosis.
Viral HBV DNA and HDV RNA loads tests 
were performed every 3-6 months during treat-
ment (M3, M6, M9, M12), at the end of the treatment 
course, and at 6 months after the end of treatment. 
HBV DNA among different patients was in the range 
1.9×102 – 7.0×106 cоpies/mL. HDV RNA viremia, as 
per our results, was 2.5×102 – 1.3 ×107copies/mL. Our 
data also showed no correlation between cirrhosis 
and disease stage and amount of HDV RNA vire-
mia (rs=0.38, p=0.54, p>0.05). HDV RNA and HBV 
DNA showed a medium scaled inverse correlation, 
i.e. higher HDV levels are usually associated with 
lower HBV viremia.
DISCUSSION
Hepatitis B vaccination programs have led to the 
trend of a gradual decrease in the incidence of hepati-
tis B worldwide. As per our results HBV was found in 
23.6% of the tested patients and compared to previ-
ous studies (HBV/HDV) in patients with chronic liv-
er disease in northeastern Bulgaria - 30.4% (12) and 
26.5% (13). This percentage is decreasing. 
The prevalence of hepatitis D according to var-
ious studies in patients with chronic liver disease 
shows variability. Various studies support a signifi-
cantly higher prevalence of concomitant HBV/HDV 
infection in patients aged 20-39 years, with an over-
all prevalence of 41.9% (14). The results we have ob-
tained show an incidence of anti-HDV Ab in 16.6% 
of HBV-infected serum samples from patients with 
chronic liver disease. In other European countries 
(Romania), concomitant HBV/HDV infection is de-
tected in 20.4% of patients with chronic hepatitis B. 
The prevalence of HDV in Europe (France, Germa-
ny, Italy, the United Kingdom) is between 8-12% of all 
of the HBsAg positive subjects tested (15). In a large 
prospective study in Greece among 4 673 patients 
with chronic hepatitis B, 2137 individuals were test-
ed for HDV and HBV/HDV positive results were ob-
tained in 4.2% of them. A significantly higher preva-
lence was found among emigrants (7.5%), compared 
to the local Greek population (2.8%) (16). In Turkey, 
serological data for anti-HDV positivity were found 
in 27.5% of patients with chronic hepatitis (17). Ac-
cording to another study in the Mediterranean ba-
sin, 14.8% of the asymptomatic HBsAg (+) patients 
are infected with HDV, with liver cirrhosis being a 
common complication (18). In 2013 a study was con-
ducted in North Carolina (USA) among 499 patients 
with chronic HBV infection and 40 of them (8%) 
were with dual HBV/ HDV infection (19).
Monitoring the spread of HBV/HDV infection 
is important because of the socioeconomic signif-
icance of these infections and the severe complica-
tions for the patients. The relative risk of developing 
fibrosis, cirrhosis and HCC, is 25 to 35 times high-
er than that of individuals with HBV monoinfection 
(20). 
We found HDV RNA positive results in 96.9% 
of all anti-HDV Ab (+) patients which is close to the 
results reported by EASL (2017), according to which 
87% of anti-HDV positive serum samples also hepa-
titis D nucleic acid positive (21).
Phylogenetic reconstructions based on HDV-
encoding sequences showed an ancient division from 
African HDV sequences - not the previously known 
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three, but eight different HDV genotypes (22). Iso-
lates of HDV genotype 1 are found in all parts of the 
world and lead to asymptomatic liver disease to ful-
minant hepatitis. HDV genotype-1 is found in Eu-
rope and North America. All of our five patients with 
exitus letalis, sequenced for HDV, were from geno-
type 1 (23). HDV genotype 2 is found mostly in Asia, 
including Japan, Taiwan, and recently - in Yakutia 
(Russia). Some viral sequences from the Taiwan and 
Okinawa Islands have been identified as genotype 2 
subtype, called genotype lib (24). HDV genotype 3 is 
isolated only in the northern parts of South America 
(Peru, Venezuela, Colombia) and is associated with 
the most severe and aggressive forms of hepatitis D. 
New data from a study of HDV-positive patients with 
genotype 3 HDV infection showed a correlation be-
tween serum HDV RNA levels and serum liver en-
zymes levels (25). Genotype 4 occurs in Japan and 
Taiwan and has heterogeneous pathogenesis. Gen-
otype 4 isolated from Okinawa, Japan is associated 
with a faster progression to cirrhosis compared to the 
predominant genotype 4 in Taiwan (26). Genotypes 
5 to 8 occur in patients from Africa who have migrat-
ed to Northern Europe (27). All genotypes of HDV 
refer to one viral serotype.
CONCLUSION
HBV and HDV, continue to be a serious health 
and social problem despite the widespread specific 
prophylaxis against HBV and the numerous strate-
gies and options for therapy. HDV infection has still 
many mysteries to discover in terms of pathogene-
sis, clinical outcome in chronic HBV/HDV infected 
individuals, as well as genotype variations and their 
role in avoiding immune elimination of the virus. All 
these unanswered questions pose a great challenge to 
the scientific thought and efforts of humankind to 
reduce and gradually eliminate viral hepatitis D.
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